Innovation

Novel Method of Discriminating Between Ventricular and Supraventricular Tachyarrhythmias

University of Pittsburgh
posted on 06/29/2009

This invention provides a method to discriminate between ventricular arrhythmia and supraventricular tachycardia by detecting an earliest arriving electrical signal following antitachycardia pacing.

Suggested Uses

  • Implantable cardiac defibrillator

Advantages

  • Better descrimination between VT and SVT which decreases the rate of inappropriate shocks for SVT.
  • Provides a better understanding of the patient’s AV and VA conduction system under various autonomic conditions (high sympathetic or vagal tones) over long periods of time.

Innovation Details
 

Detailed Description

An implantable cardiac defibrillator provides atrioventricular and ventriculoatrial pacing bursts to determine if an arrhythmia with a 1 :1 atrial to ventricular relationship is due to ventricular tachycardia or supraventricular tachycardia. This discrimination capability reduces the incidence of inappropriate shocks from dual- chamber implantable cardiac defibrillators to near zero and provides a method to differentially diagnose supraventricular tachycardia from ventricular tachycardia.

File Number: 906 

Disease: Cardiovascular and Circulatory System


IP Protection

Patent Number(s): PCT/US2008/011437

License Online

This innovation currently is not available for online licensing. Please contact Alexander Ducruet at University of Pittsburgh for more information.

Request more info via email request more info
People

Case Manager:

Alexander Ducruet Alexander Ducruet

Innovations (91)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

7,840 members 17,176 innovations 152 organizations

Browse

Linda L. Restifo, M.D., Ph.D. - University of Arizona

"I want to say again how happy I am about the iBridge Network mechanism. This seems ideal for NeuronMetrics and I'm very pleased we will be part of this venture."  read more...